The GenCRISPR Ultra product line is a comprehensive collection of Cas-based nucleases with enhanced gene editing performance.
GenScript’s Ultra product line supports progression of gene-editing research through two quality-controlled product tiers: research use only (RUO) and GMP compliant.
The Ultra RUO products provide cost-effective solutions for basic research applications. With stringent quality controls, ISO9001, ISO13485 and GMP manufacturing guidelines, the GMP products are ideal solutions for pre-clinical and clinical applications.
| Cas9 Standard | Cas9 Ultra | |
|---|---|---|
| Customizable | Yes | Yes |
| Gene Editing Efficiency | ++ | +++ |
| Quality System | Controlled ISO 13485 |
Controlled |
| Endotoxin levels | ≤100 EU/mg | ≤10 EU/mg |
| Enhancements |
Tag-free |
|
| Applications | Research | Research, Pre-clinical, Commercialization |
| Documentation | Certificate of Analysis | Basic documentation Complete |
| Cas9 Ultra RUO |
Cas9 Ultra GMP Grade |
|
|---|---|---|
| Customizable | √ | √ |
| Application | Research | Commercialization |
| Purity | ≥ 90 % | ≥ 95 % |
| Manufacturing | Controlled | GMP complaint |
| Quality Management System | + | +++ |
Ultra Cas9 N-NLS Nuclease
| Cat. No. | Product Name | Quantity | Price |
|---|---|---|---|
Z03621-0.5 |
GenCRISPR™ Ultra NLS-Cas9-Research - 0.5 mg |
$695.00 |
|
Z03621-1 |
GenCRISPR™ Ultra NLS-Cas9-Research - 1 mg |
$1181.50 |
|
Z03621-5 |
GenCRISPR™ Ultra NLS-Cas9-Research - 5 mg | - | |
Z03623-1 |
GenCRISPR™ Ultra NLS-Cas9-basic GMP - 1 mg |
$2955.00 |
|
Z03623-2.5 |
GenCRISPR™ Ultra NLS-Cas9-basic GMP - 2.5 mg | - | |
Z03623-5 |
GenCRISPR™ Ultra NLS-Cas9-basic GMP - 5 mg | - |
Ultra eSpCas9 2NLS Nuclease
| Cat. No. | Product Name | Quantity | Price |
|---|---|---|---|
Z03622-0.5 |
GenCRISPR™ Ultra eSpCas9-2NLS-Research - 0.5 mg |
$1245.00 |
|
Z03622-1 |
GenCRISPR™ Ultra eSpCas9-2NLS-Research - 1 mg |
$2116.50 |
|
Z03622-5 |
GenCRISPR™ Ultra eSpCas9-2NLS-Research - 5 mg | - |
Ultra Cas9 knock-out efficiency in cell lines
Figure 1: RAB11A and TRAC genes knock-out in 293T cells by electroporation
Ultra Cas9 knock-in efficiency in cell lines
Figure 2: dsDNA knock-in at the RAB11A site in Jurkat cells by electroporation
Ultra Cas9 knock-out efficiency in T cells
Figure 3: Gene knock-out in T cells
Ultra eSpCas9-2NLS knock-out efficiency in cell lines
Figure 4: TRAC knock-out in 293T cells by electroporation
Ultra eSpCas9-2NLS Low off-target efficiency in cell lines
Figure 5: Off-target efficiency at the OT1 and OT2 sites of 293T cells
